HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Brands Should Be Forces For Good, But Growth First – P&G’s Marc Pritchard

Executive Summary

Unlike others in the industry, and arguably P&G in recent memory, P&G brands are putting growth before good in the “virtuous circle” equation as competitors lose sight of innovation and macroeconomic conditions worsen globally.

You may also be interested in...



US Q2 Consumer Health Earnings Preview: Horizon Brightens Beyond Current Questions, Challenges?

Consumer health product firms’ vistas include challenges of supply chain disruptions lingering from pandemic’s impact as well as potential for marketplace restrictions as additional varieties of the novel coronavirus spread. Clouds also include shifts in consumer spending, increases in costs caused by inflation and foreign exchange headwinds as the value of the US dollar strengthens against other currencies.

In-House Advertising For Secret Shows New Model For Marketing P&G Brands

Gillette’s New ‘Best Men Can Be’ Ad Goes Viral, Drawing Mixed Praise, Boycott Threats

Gillette’s polarizing new video, which challenges men to “do more” to address behavior broadly painted as toxic masculinity, has elicited fervid reactions from all corners of the Internet. Whether the P&G brand’s boldness pays off remains to be seen, but it adds fuel to a growing debate: Should brands insert themselves into today’s highly politicized climate, and can they afford not to?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel